Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Diasorin SpA's pretax income for the
three
months ended in Mar. 2026 was €51 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was €191 Mil.
Diasorin SpA's pretax margin was 17.77%.
During the past 13 years, Diasorin SpA's highest Pretax Margin was 36.47%. The lowest was 16.19%. And the median was 28.79%.
During the past 13 years, Diasorin SpA's highest Pretax Margin was 36.47%. The lowest was 16.19%. And the median was 28.79%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA Pre-Tax Income Related Terms
Diasorin SpA Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIAM vs TMO, DHR, IDXX: Pre-Tax Income Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Pre-Tax Income vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €191 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (CHIX:DIAM) has a Pre-Tax Income of €191 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Pre-Tax Income too high?
Diasorin SpA's current Pre-Tax Income is €191 Mil. Overall, Diasorin SpA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Pre-Tax Income compare to TMO and DHR?
Diasorin SpA's Pre-Tax Income of €191 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Medical Diagnostics & Research company?
A good Pre-Tax Income depends on the Medical Diagnostics & Research industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Pre-Tax Income is €191 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €92.04, compared to a current price of €72.48 — trading 21.3% below its estimated fair value. The current Pre-Tax Income is €191 Mil. Diasorin SpA's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current Pre-Tax Income is €191 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €72.48 is trading 21.3% below its estimated GF Value™ of €92.04.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
Pre-Tax Income: €191 Mil
GF Value™: €92.04 vs. price of €72.48 (21.3% below fair value)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
77GF Score
Get the complete analysis for CHIX:DIAM
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
